Prevalence of Human Papillomavirus in 5,072 Consecutive Cervical SurePath Samples Evaluated with the Roche Cobas HPV Real-Time PCR Assay

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Preisler, Sarah ^a   Rebolj, Matejka ^b   Untermann, Anette ^a   Ejegod, Ditte Møller ^a   Lynge, Elsebeth ^b   Rygaard, Carsten ^a   Bonde, Jesper ^a  

^a Mental Health Center Glostrup   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER RISK; CULTURE MEDIUM; DENMARK; FEMALE; GENOTYPE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMAGING SYSTEM; MAJOR CLINICAL STUDY; MASS SCREENING; PAPILLOMAVIRUS INFECTION; POPULATION RESEARCH; PREVALENCE; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; UTERINE CERVIX CYTOLOGY;

AGED; CERVIX UTERI; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; REAL-TIME POLYMERASE CHAIN REACTION; UTERINE CERVICAL NEOPLASMS;

EID: 84875310611     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059765     Document Type: Article

References (33)

1. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, et al. (2008) Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26Suppl 10: K29-K41.
2. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, et al. (2010) Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 11: 249-257.
3. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, et al. (2012) Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 13: 78-88.
4. Lynge E, Rebolj M, (2009) Primary HPV screening for cervical cancer prevention: results from European trials. Nat Rev Clin Oncol 6: 699-706.
5. Solomon D, Schiffman M, Tarone R, (2001) Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 93: 293-299.
6. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, et al. (2009) Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 124: 516-520.
7. Kinney W, Stoler MH, Castle PE, (2010) Special commentary: patient safety and the next generation of HPV DNA tests. Am J Clin Pathol 134: 193-199.
8. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, et al. (2009) A review of human carcinogens-Part B: biological agents. Lancet Oncol 10: 321-322.
9. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, et al. (2004) Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111: 278-285.
10. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, et al. (2012) American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 137: 516-542.
11. Wright TC Jr, Stoler MH, Behrens CM, Apple R, Derion T, et al. (2012) The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol 206: 46.e1-46.e11.
12. Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, et al. (2011) Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 12: 880-890.
13. Wright TC Jr, Stoler MH, Sharma A, Zhang G, Behrens C, et al. (2011) Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am J Clin Pathol 136: 578-586.
14. Szarewski A, Mesher D, Cadman L, Austin J, Ashdown-Barr L, et al. (2012) Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the predictors 2 study. J Clin Microbiol 50: 1867-1873.
15. Lapierre SG, Sauthier P, Mayrand MH, Dufresne S, Petignat P, et al. (2012) Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with cobas 4800 HPV and Hybrid Capture 2 tests for detection of high-grade lesions of the uterine cervix. J Clin Microbiol 50: 1240-1244.
16. Ovestad IT, Vennestrom U, Andersen L, Gudlaugsson E, Munk AC, et al. (2011) Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3. Gynecol Oncol 123: 278-283.
17. Castle PE, Sadorra M, Lau T, Aldrich C, Garcia FA, et al. (2009) Evaluation of a prototype real-time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping. J Clin Microbiol 47: 3344-3347.
18. Gage JC, Sadorra M, Lamere BJ, Kail R, Aldrich C, et al. (2012) Comparison of the cobas Human Papillomavirus (HPV) test with the hybrid capture 2 and linear array HPV DNA tests. J Clin Microbiol 50: 61-65.
19. Clemmesen J, Nielsen A, (1951) The social distribution of cancer in Copenhagen, 1943 to 1947. Br J Cancer 5: 159-171.
20. Styregruppen for DKLS (2011) Årsrapport DKLS 2010: Dansk Kvalitetsdatabase for Livmoderhalskræftscreening [Annual report 2010: Danish Quality Assurance database for cervical cancer screening]. URL: https://www.sundhed.dk/Fil.ashx?id=15486&ext=pdf&navn=DKLS_aarsrapport_2010.pdf. Last accessed: 21 November 2011.
21. Bjerregaard B, Larsen OB, (2011) The Danish Pathology Register. Scand J Public Health 39: 72-74.
22. Cobas® HPV Test [package insert]. Branchburg, NJ, USA: Roche Molecular Systems. Available: http://e-labdoc.roche.com, last accessed for the study august 2012.
23. QIASymphony [package insert]. Gaithersburg, MD, USA: Qiagen. Available: www.qiagen.com/literature/render.aspx?id=201094. Accessed 21 August 2012.
24. Franceschi S, Clifford GM, (2005) Re: A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst 97: 938-939.
25. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, et al. (2010) Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 202: 1789-1799.
26. Heideman DA, Hesselink AT, Berkhof J, van Kemenade F, Melchers WJ, et al. (2011) Clinical validation of the cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol 49: 3983-3985.
27. Kjaer SK, Breugelmans G, Munk C, Junge J, Watson M, et al. (2008) Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer 123: 1864-1870.
28. Austin RM (undated) URL: http://laboratory-manager.advanceweb.com/features/top-story/liquid-based-cytology-vs-conventional-cytology.aspx?CP=3. Accessed 14 March 2012.
29. Wong AA, Fuller J, Pabbaraju K, Wong S, Zahariadis G, (2012) Comparison of the hybrid capture 2 and cobas 4800 tests for detection of high-risk human papillomavirus in specimens collected in PreservCyt medium. J Clin Microbiol 50: 25-29.
30. Park Y, Lee E, Choi J, Jeong S, Kim HS, (2012) Clinical performances of the Abbott RealTime High Risk HPV, Roche Cobas HPV and Hybrid Capture 2 assays compared to direct sequencing and genotyping of HPV DNA. J Clin Microbiol 50: 2359-2365.
31. Martinez SB, Palomares JC, Artura A, Parra M, Cabezas JL, et al. (2012) Comparison of the Cobas 4800 Human Papillomavirus test against a combination of the Amplicor Human Papillomavirus and the Linear Array tests for detection of HPV types 16 and 18 in cervical samples. J Virol Methods 180: 7-10.
32. Lindemann ML, Dominguez MJ, de Antonio JC, Sandri MT, Tricca A, et al. (2012) Analytical comparison of the cobas HPV Test with Hybrid Capture 2 for the detection of high-risk HPV genotypes. J Mol Diagn 14: 65-70.
33. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, et al. (2009) Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 101: 88-99.